Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OKI-179 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OKI-179 | DRUG | OKI-179 single agent |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
OKI-179 is an investigational small molecule being studied for the treatment of advanced solid tumors, including tumors with RAS mutations and NRAS-mutated melanoma. It is being developed by OnKure Therapeutics, Inc. (NASDAQ: OKUR) and is currently in clinical development.
OKI-179 is being developed by OnKure Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker OKUR. The company is conducting clinical trials to evaluate the drug in patients with advanced solid tumors and RAS pathway mutations.
OKI-179 is in Phase 1 clinical development. It has been studied in a completed Phase 1 trial for advanced solid tumors and a completed Phase 1/Phase 2 trial for RAS-mutated and NRAS-mutated cancers. It remains investigational and is not FDA approved.
OKI-179 has been studied in two clinical trials. NCT03931681 was a Phase 1 study in patients with advanced solid tumors. NCT05340621, called NAUTILUS, was a Phase 1/Phase 2 study of OKI-179 plus binimetinib in patients with advanced solid tumors in the RAS pathway and NRAS-mutated melanoma.
OKI-179 is being studied in combination with binimetinib in the NAUTILUS trial (NCT05340621). This trial evaluated OKI-179 plus binimetinib in patients with advanced solid tumors in the RAS pathway and in NRAS-mutated melanoma. The combination was studied in a Phase 1b and Phase 2 setting.